GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Price-to-Tangible-Book

Edgewise Therapeutics (Edgewise Therapeutics) Price-to-Tangible-Book : 3.16 (As of May. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Price-to-Tangible-Book?

As of today (2024-05-18), Edgewise Therapeutics's share price is $18.11. Edgewise Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $5.74. Hence, Edgewise Therapeutics's Price to Tangible Book Ratio of today is 3.16.

The historical rank and industry rank for Edgewise Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

EWTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.25   Med: 1.85   Max: 5.22
Current: 3.16

During the past 5 years, Edgewise Therapeutics's highest Price to Tangible Book Ratio was 5.22. The lowest was 1.25. And the median was 1.85.

EWTX's Price-to-Tangible-Book is ranked worse than
55.04% of 1230 companies
in the Biotechnology industry
Industry Median: 2.81 vs EWTX: 3.16

A closely related ratio is called PB Ratio. As of today, Edgewise Therapeutics's share price is $18.11. Edgewise Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $5.74. Hence, Edgewise Therapeutics's P/B Ratio of today is 3.16.


Edgewise Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Edgewise Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Price-to-Tangible-Book Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 2.76 1.63 2.42

Edgewise Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.58 1.25 2.42 3.18

Competitive Comparison of Edgewise Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Edgewise Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edgewise Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's Price-to-Tangible-Book falls into.



Edgewise Therapeutics Price-to-Tangible-Book Calculation

Edgewise Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=18.11/5.735
=3.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Edgewise Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3415 Colorado Avenue, Boulder, CO, USA, 80303
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Executives
John R Moore officer: General Counsel 3200 WALNUT ST, BOULDER CO 80301
Alan J Russell director, officer: Chief Scientific Officer 3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan officer: Chief Business Officer 3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch director, officer: President and CEO 3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan officer: CMO C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran officer: Chief Development Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017